Contraindicated (one)bortezomib will increase the level or impact of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Solid or average CYP2C19 inhibitors may boost mavacamten systemic exposure, leading to heart failure as a consequence of systolic dysfunction. levoketoconazole will increase the degree or influence of bortezomib by influencing hepatic/intesti... https://fustin68901.blogstival.com/49146312/the-5-second-trick-for-dup-747